Benralizumab
- Generic Name
- Benralizumab
- Brand Names
- Fasenra
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1044511-01-4
- Unique Ingredient Identifier
- 71492GE1FX
- Background
Benralizumab is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin 5 receptor (IL-5R) expressed on eosinophils and basophils. It inhibits the binding of IL-5 as well as the hetero-oligomerization of the alpha and beta subunits of the IL-5R, thus blocking, signal transd...
- Indication
Benralizumab is indicated as a maintenance treatment of patients 12 years or older with severe asthma and an eosinophilic phenotype. The pathology of severe asthma with eosinophilic phenotype is also denotated as TH2-high phenotype. The patients with this phenotype are characterized by the expression of IL-5 and IL-13, airway hyperresponsiveness, responsiven...
- Associated Conditions
- Severe Eosinophilic Asthma
- Associated Therapies
- -
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
- Conditions
- Interventions
- First Posted Date
- 2020-09-17
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT04552288
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center Suffolk - Hauppauge (Limited Protocol Activities), Hauppauge, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
PK/PD and Long Term Safety Study of Benralizumab in Children With Severe Eosinophilic Asthma
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT04305405
- Locations
- 🇯🇵
Research Site, Zentsuji-shi, Japan
A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)
- Conditions
- Interventions
- First Posted Date
- 2019-12-09
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT04191304
- Locations
- 🇬🇧
Research Site, London, United Kingdom
NAsal Polyps: Inflammatory & Molecular Phenotyping of Responders to Benralizumab
- First Posted Date
- 2019-12-04
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Humanitas Clinical and Research Center
- Target Recruit Count
- 14
- Registration Number
- NCT04185012
- Locations
- 🇮🇹
Humanitas Clinical and Research Hospital, Rozzano, MI, Italy
Benralizumab Exacerbation Study
- First Posted Date
- 2019-09-25
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- NHS Greater Glasgow and Clyde
- Target Recruit Count
- 157
- Registration Number
- NCT04102800
- Locations
- 🇬🇧
Belfast City Hospital, Belfast, United Kingdom
🇬🇧Birmingham Heartlands Hospital, Birmingham, United Kingdom
🇬🇧Gartnavel General Hospital, Glasgow, United Kingdom
Acute Exacerbations Treated With BenRAlizumab (The ABRA Study)
- First Posted Date
- 2019-09-23
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 158
- Registration Number
- NCT04098718
- Locations
- 🇬🇧
Oxford University Hospitals NHS Foundation Trust, Oxford, Oxfordshire, United Kingdom
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations
- Conditions
- Interventions
- First Posted Date
- 2019-08-12
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 689
- Registration Number
- NCT04053634
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics
- First Posted Date
- 2019-05-16
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 81
- Registration Number
- NCT03953300
- Locations
- 🇬🇧
Research Site, Wythenshawe, United Kingdom
Evaluating the Effect of Benralizumab in Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI
- Conditions
- Interventions
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Dr. Grace Parraga
- Target Recruit Count
- 29
- Registration Number
- NCT03733535
- Locations
- 🇨🇦
Robarts Research Institute; The University of Western Ontario; London Health Sciences Centre, London, Ontario, Canada
Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- University of Rostock
- Target Recruit Count
- 20
- Registration Number
- NCT03652376
- Locations
- 🇩🇪
University of Rostock, Rostock, Mecklenburg-Vorpommern, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.